Blood donor screening: Deferral criteria


A major goal of transfusion medicine practice has been to reduce the risk of transfusion-transmitted infection to as low a level as possible [1,2]. In order to approach the desired level of zero risk from transfused allogeneic blood, multiple layers of safety are needed. Methods used in attempting to maximize safety from donated allogeneic units include donor selection criteria, donor medical history interview, the confidential unit exclusion (CUE) option, donor deferral registries, laboratory testing of donated units, donor initiated telephone call backs, and modification of the blood unit after collection, either by leukocyte removal or physicochemical procedures for pathogen inactivation [3,4].

In addition to assuring that the donated unit will not cause any adverse consequences for transfusion recipients, the evaluation of each prospective blood donor includes procedures to assure that the donor will not suffer any adverse reactions from the donation itself [5], or from hematopoietic growth factors that may be employed to facilitate such donations [6].

Over the past three decades, procedures used to evaluate donors have changed dramatically. The increased awareness of potential spread of infectious disease by blood transfusion has resulted in much more elaborate donor screening for the purpose of protecting the transfusion recipient [5]. At the same time, experience from autologous donation programs has lessened the concern about adverse donor reactions [7]. (See "Surgical blood conservation: Preoperative autologous blood donation".)

In the last decade, standard serological testing of donated blood for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) has been supplemented by the addition of nucleic acid testing of pools of donations for HIV and HCV RNA, which allows for detection of additional infectious units [8]. The current per unit risk estimate for acquiring HIV from transfusion is one in 1.5 to one in 2.1 million and for HCV is one in one million to one in two million [9,10].

Prior to 2010, risks for Hepatitis B Virus (HBV) were estimated to range from one in 58,000 to one in 269,000. Since that time, as the result of additional donation testing, these risks are now estimated to range from one in 205,000 to one in 355,000 [9,11-13]. Risk for human T-lymphotropic virus (HTLV) is estimated to be about one in two million when the older published risk estimate (one in 641,000) is adjusted for the fact that only one-third of potentially infectious units actually transmit HTLV infection, due to loss of viable virus upon blood component storage [12,14].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Mar 26, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
  1. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904.
  2. McCullough J. The nation's changing blood supply system. JAMA 1993; 269:2239.
  3. Kleinman S. Donor selection and screening procedures. In: Safety Current Challenges, Nance SJ (Ed), American Association of Blood Banks, Bethesda, MD 1992. p.169.
  4. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361:161.
  5. Kleinman S. Donor Screening Procedures. In: Practice of Transfusion Medicine, 3rd ed, Petz L, Swisher S, Kleinman S, et al (Eds), Churchill-Livingstone, New York 1996. p.245.
  6. McCullough J, Kahn J, Adamson J, et al. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008; 48:2008.
  7. Goldfinger D, Capon S, Czer L, et al. Safety and efficacy of preoperative donation of blood for autologous use by patients with end-stage heart or lung disease who are awaiting organ transplantation. Transfusion 1993; 33:336.
  8. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165.
  9. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.
  10. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495.
  11. Glynn S. Residual risks for hepatitis and HIV and unreported deferrable risk in US blood donors. Canadian Blood Services Consensus Conference Proceedings: "Blood-borne HIV and Hepatitis: optimizing the donor selection process". Ottawa, Ontario, Canada, November 7-9, 2001.
  12. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685.
  13. Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609.
  14. Donegan E, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34:478.
  15. Standards for blood banks and transfusion services, 18th ed, Price TH (Ed), American Association of Blood Banks, Bethesda, MD 2008.
  16. US Department of Health and Human Services, Food and Drug Administration. The code of federal regulations, Washington, DC: US Government Printing Office, 2008 (revised annually).
  17. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155.
  18. Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993; 33:61.
  19. Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis 1994; 170:231.
  20. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:798.
  21. Whittaker S, Carter N, Arnold E, et al. Understanding the meaning of permanent deferral for blood donors. Transfusion 2008; 48:64.
  22. Kaplan HS, Kleinman SH. AIDS: blood donor studies and screening methods. In: Infection, Immunity and Blood Transfusion, Barker LF, Dodd RY (Eds), Alan R Liss, New York 1985. p.297.
  23. SCHAFER IA, MOSLEY JW. A study of viral hepatitis in a penal institution. Ann Intern Med 1958; 49:1162.
  24. Krugman S, Friedman H, Lattimer C. Hepatitis A and B: serologic survey of various population groups. Am J Med Sci 1978; 275:249.
  25. American Association of Blood Banks, American Red Cross, Council of Community Blood Centers: Joint statement on acquired immune deficiency syndrome related to transfusion. January 13, 1983.
  26. Cherubin CE, Prince AM. Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion 1971; 11:25.
  27. Szmuness W, Prince AM, Brotman B, Hirsch RL. Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis 1973; 127:17.
  28. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77:691.
  29. Barker LF. International forum: Which criteria must be fulfilled for a donation or a donor to be considered voluntary. Vox Sang 1978; 34:363.
  30. Glynn SA, Williams AE, Nass CC, et al. Attitudes toward blood donation incentives in the United States: implications for donor recruitment. Transfusion 2003; 43:7.
  31. Mayo DJ. Evaluating donor recruitment strategies. Transfusion 1992; 32:797.
  32. Sanchez AM, Ameti DI, Schreiber GB, et al. The potential impact of incentives on future blood donation behavior. Transfusion 2001; 41:172.
  33. Strauss RG. Blood donations, safety, and incentives. Transfusion 2001; 41:165.
  34. Glynn SA, Smith JW, Schreiber GB, et al. Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 2001; 41:736.
  35. Williams AE, Glynn SA, Bethel J, Ameti DI. Blood donation incentives: attitudes and risk relationships among first time and repeat whole blood donors (abstract). Transfusion 2000; 40:1S.
  36. Doll LS, Petersen LR, White CR, Ward JW. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. The HIV Blood Donor Study Group. Transfusion 1991; 31:704.
  37. Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med 1989; 321:917.
  38. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967.
  39. Schreiber GB, Sharma UK, Glynn SA, et al. Evaluation of donors who give primarily for HIV testing (abstract). Transfusion 2001; 41(Supplement):35S.
  40. Tan L, Khan MK, Hawk JC 3rd. Use of blood therapeutically drawn from hemochromatosis patients. Council on Scientific Affairs, American Medical Association. Transfusion 1999; 39:1018.
  41. 21 CFR 640.120 (April, 2000).
  42. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA 2001; 286:1475.
  43. Barton JC, Grindon AJ, Barton NH, Bertoli LF. Hemochromatosis probands as blood donors. Transfusion 1999; 39:578.
  44. Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 2001; 41:123.
  45. Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion 2003; 43:1538.
  46. Mayo DJ, Rose AM, Matchett SE, et al. Screening potential blood donors at risk for human immunodeficiency virus. Transfusion 1991; 31:466.
  47. Petersen LR, Lackritz E, Lewis WF, et al. The effectiveness of the confidential unit exclusion option. Transfusion 1994; 34:865.
  48. Korelitz JJ, Williams AE, Busch MP, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion 1994; 34:870.
  49. Pindyck J, Waldman A, Zang E, et al. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation. Transfusion 1985; 25:3.
  50. Zou S, Notari EP 4th, Musavi F, et al. Current impact of the confidential unit exclusion option. Transfusion 2004; 44:651.
  51. Grossman BJ, Springer KM. Blood donor deferral registries: highlights of a conference. Transfusion 1992; 32:868.
  52. Casale G, Bignamini M, de Nicola P. Does blood donation prolong life expectancy? Vox Sang 1983; 45:398.
  53. Salonen JT, Tuomainen TP, Salonen R, et al. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998; 148:445.
  54. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 2002; 42:1135.
  55. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284:229.
  56. Edgren G, Tran TN, Hjalgrim H, et al. Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion 2007; 47:2017.
  57. Food and Drug Administration. Center for Biologics Evaluation and Research, Division of Inspections and Surveillance. Biological Product Deviation Reports-Annual-Summary for Fiscal year 2007.
  58. Dunbar N, Katz J, Nambiar A. The potential impact of new donor height and weight criteria on young donor eligibility and faint or prefaint reaction rates. Transfusion 2011; 51:737.
  59. Tomasulo PA, Anderson AJ, Paluso MB, et al. A study of criteria for blood donor deferral. Transfusion 1980; 20:511.
  60. Yuan S, Gornbein J, Smeltzer B, et al. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections. Transfusion 2008; 48:1213.
  61. Eder AF, Dy BA, Kennedy JM, et al. Improved safety for young whole blood donors with new selection criteria for total estimated blood volume. Transfusion 2011; 51:1522.
  62. (Accessed on January 14, 2013).
  63. Pi DW, Krikler SH, Sparling TG, et al. Reappraisal of optimal hemoglobin standards for female blood donors in Canada. Transfusion 1994; 34:7.
  64. Holland PV. Measuring the volume of packed RBCs in donors. Transfusion 2001; 41:309.
  65. Standards for blood banks and transfusion services, 25th ed, Price TH (Ed), American Association of Blood Banks, Bethesda, MD 2008.
  66. Wood EM, Kim DM, Miller JP. Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion 2001; 41:353.
  67. Mendrone A Jr, Sabino EC, Sampaio L, et al. Anemia screening in potential female blood donors: comparison of two different quantitative methods. Transfusion 2009; 49:662.
  68. Pottgiesser T, Specker W, Umhau M, et al. Recovery of hemoglobin mass after blood donation. Transfusion 2008; 48:1390.
  69. Gordeuk VR, Brittenham GM, Bravo J, et al. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion 1990; 30:239.
  70. Bianco C, Brittenham G, Gilcher RO, et al. Maintaining iron balance in women blood donors of childbearing age: summary of a workshop. Transfusion 2002; 42:798.
  71. Bier-Ulrich AM, Haubelt H, Anders C, et al. The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo-controlled double-blind study. Transfusion 2003; 43:405.
  72. Mast AE, Foster TM, Pinder HL, et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48:2197.
  73. Cable RG, Glynn SA, Kiss JE, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011; 51:511.
  74. Radtke H, Tegtmeier J, Röcker L, et al. Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44:1427.
  75. Magnussen K, Bork N, Asmussen L. The effect of a standardized protocol for iron supplementation to blood donors low in hemoglobin concentration. Transfusion 2008; 48:749.
  76. Maghsudlu M, Nasizadeh S, Toogeh GR, et al. Short-term ferrous sulfate supplementation in female blood donors. Transfusion 2008; 48:1192.
  77. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion 2006; 46:1667.
  78. Brittenham GM. Iron deficiency in whole blood donors. Transfusion 2011; 51:458.
  79. Benjamin RJ, Dy BA, Kennedy JM, et al. The relative safety of automated two-unit red blood cell procedures and manual whole-blood collection in young donors. Transfusion 2009; 49:1874.
  80. Högler W, Mayer W, Messmer C, et al. Prolonged iron depletion after allogeneic 2-unit RBC apheresis. Transfusion 2001; 41:602.
  81. Radtke H, Mayer B, Röcker L, et al. Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44:1463.
  82. O'Meara A, Infanti L, Stebler C, et al. The value of routine ferritin measurement in blood donors. Transfusion 2011; 51:2183.
  83. Pasricha SR, McQuilten ZK, Keller AJ, Wood EM. Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. Transfusion 2011; 51:2709.
  84. Mast AE, Lee TH, Schlumpf KS, et al. The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. Br J Haematol 2012; 156:388.
  85. Stohlawetz P, Stiegler G, Jilma B, et al. Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998; 38:454.
  86. Strauss RG. Risks of clinically significant thrombocytopenia and/or lymphocytopenia in donors after multiple plateletpheresis collections. Transfusion 2008; 48:1274.
  87. Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41:756.
  88. Katz L, Palmer K, McDonnell E, Kabat A. Frequent plateletpheresis does not clinically significantly decrease platelet counts in donors. Transfusion 2007; 47:1601.
  89. Richa E, Krueger P, Burgstaler EA, et al. The effect of double- and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008; 48:1325.
  90. Bolan CD, Greer SE, Cecco SA, et al. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001; 41:1165.
  91. Bolan CD, Cecco SA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. Transfusion 2003; 43:1414.
  92. Laspina SJ, Browne MA, McSweeney EN, et al. QTc prolongation in apheresis platelet donors. Transfusion 2002; 42:899.
  93. Despotis GJ, Goodnough LT, Dynis M, et al. Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program. Vox Sang 1999; 77:24.
  94. Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003; 43:1403.
  95. Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002; 42:935.
  96. Kishimoto M, Ohto H, Shikama Y, et al. Treatment for the decline of ionized calcium levels during peripheral blood progenitor cell harvesting. Transfusion 2002; 42:1340.
  97. Buchta C, Macher M, Bieglmayer C, et al. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003; 43:1615.
  98. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001; 98:1339.
  99. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98:1346.
  100. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002; 359:2145.
  101. Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003; 43:598.
  102. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809.
  103. Newman BH. Donor reactions and injuries from whole blood donation. Transfus Med Rev 1997; 11:64.
  104. Tomita T, Takayanagi M, Kiwada K, et al. Vasovagal reactions in apheresis donors. Transfusion 2002; 42:1561.
  105. Wieling W, France CR, van Dijk N, et al. Physiologic strategies to prevent fainting responses during or after whole blood donation. Transfusion 2011; 51:2727.
  106. Trouern-Trend JJ, Cable RG, Badon SJ, et al. A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999; 39:316.
  107. Newman BH, Graves S. A study of 178 consecutive vasovagal syncopal reactions from the perspective of safety. Transfusion 2001; 41:1475.
  108. Newman BH. Vasovagal reactions in high school students: findings relative to race, risk factor synergism, female sex, and non-high school participants. Transfusion 2002; 42:1557.
  109. Newman BH, Siegfried BA, Buchanan LA. Donor reactions among African-American and Caucasian first-time whole-blood donors. Transfusion 2005; 45:1398.
  110. Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008; 299:2279.
  111. Hanson SA, France CR. Predonation water ingestion attenuates negative reactions to blood donation. Transfusion 2004; 44:924.
  112. Ando S, Kawamura N, Matsumoto M, et al. Simple standing test predicts and water ingestion prevents vasovagal reaction in the high-risk blood donors. Transfusion 2009; 49:1630.
  113. Newman B, Tommolino E, Andreozzi C, et al. The effect of a 473-mL (16-oz) water drink on vasovagal donor reaction rates in high-school students. Transfusion 2007; 47:1524.
  114. Tomasulo P, Kamel H, Bravo M, et al. Interventions to reduce the vasovagal reaction rate in young whole blood donors. Transfusion 2011; 51:1511.
  115. Hanson SA, France CR. Social support attenuates presyncopal reactions to blood donation. Transfusion 2009; 49:843.